FGF21 and steatosis: The drug candidates can on a top level be divided into three main categories 1) metabolic compounds with effect on steatosis (PPAR agonists, ACC inhibitors, Ketohexokinase inhibitors, DGAT2 inhibitors, SCD1 inhibitors, SGTL2 inhibitors, GLP-1 receptor agonist or derivates thereof, THRb agonists, FGF19, and FGF21 analogues etc.); 2) compounds that target inflammation (AOC3 inhibitors, CCR2/5 inhibitors, Gal3 inhibitors); and 3) compounds with anti-fibrotic effect (FXR agonist, FGF19, and FGF21 analogues, ASK-1 inhibitors, Loxl2 inhibitors).